Taken together these data suggest that compromised immune tolerance in IBD caused by NOD2 and ATG16L1 variants (35) may be modulated by ganglioside to resolve mucosal inflammation independent of the presence of risk alleles. Here, ATG16L1 is linked to inflammatory bowel disease.